
Cultivating a Culture of Human Ingenuity in the Age of AI
At Sanofi, we have undergone a journey of modernization that positions us to deliver robust innovation over the next decade—advancing health for millions of people around the world. Our success depends as much on what we do as how we do it. When our core capabilities match the speed and sophistication of our science and technology, we accelerate the pace of innovation, decision making, and access to medicines and vaccines.
Our unwavering purpose—chasing the miracles of science to improve people's lives—fuels our high-performance culture and drives us toward excellence.
Fiercely Prioritizing Time
Patients are waiting for life-changing—and in some instances life-saving—medicines. This reality demands that we create a culture that rewards the fierce prioritization of our efforts. We have given our employees the power to make deliberate and sometimes difficult choices about what truly matters. In direct alignment with our purpose, we assess every project against its potential to improve patient outcomes. But a culture isn't created overnight; it takes practice and intention.
First, we tackled complexity head-on. For the past three years, our companywide simplification initiative has dramatically reduced administrative processes, accelerated scientific workflows, improved data management, and streamlined cross-sector strategic planning. This transformation allowed us to identify and address operational challenges through strategic investments and targeted solutions—and it was guided by our employees.
Second, we built a culture that values impact over broad activity. As AI increasingly handles routine tasks that once consumed our time, we've shifted our focus to uniquely human strengths: patient-centered action, bold thinking, and collaborative leadership. This represents a fundamental shift to recognize thoughtful work as inherently productive.
Innovating Beyond the Science
Innovation at Sanofi extends far beyond our laboratories and research facilities—it requires every employee to rethink how we work, collaborate, and serve patients worldwide. Today we are innovating beyond the science by embracing AI and upskilling our employees to leverage the technology to its fullest potential.
In 2023, we launched Plai, an industry-leading AI-powered platform developed in partnership with Aily Labs, which solved the critical challenge of breaking down internal silos and democratizing access to information. In line with our responsible AI guiding principles, Plai delivers real-time, reactive data interactions and gives an unprecedented 360-degree view across all Sanofi activities, empowering more than 30,000 employees to make faster, intelligence-driven decisions.
To embed this capability deeply within our organization, we brought employees along the journey with a 10-week immersive training program providing in-depth knowledge of the power of large language models and inspiring new applications across our business.
We aimed to create an environment that allows our teams to reimagine how AI could inform their everyday decisions, improve their productivity, and accelerate our development timelines. We wanted them to think about how we can change the pace of our business. The democratization of information has been a true game changer for us at Sanofi—not only in how we work together but also in our collective mindset.
Our experience with rolling out Plai has provided us with a vision of how innovating beyond science is helping us shape our future. We must continue to reimagine every aspect of our business to serve patients worldwide.
Transforming Talent
Through strategic initiatives that promote both calculated risk-taking and professional growth, we're reshaping how our teams collaborate, make decisions, and ultimately serve patients. Our approach combines the agility of a startup with the resources of a global health care leader, creating an environment where bold ideas flourish and talent flows to where it can make the greatest impact.
Our Thoughtful Risk-Taking (TRT) framework equips our teams with the resources they need to make informed decisions with confidence, empowering employees at all levels to weigh options carefully, then act decisively in the best interests of patients. This approach promotes psychological safety, while encouraging bold action.
Teams worldwide have embraced TRT as they work to bring life-changing medicines to patients who simply cannot wait for the often drawn-out decision-making process that exists in large companies. We've already seen remarkable initiatives emerge, including innovative compassionate-use programs that provide patients with early access to select medicines, addressing unmet medical needs faster than traditional approaches would allow.
We have also enabled dynamic resourcing to staff important projects with the highest need through our Gig program. This initiative allows employees to volunteer for short-term assignments that tap into specialized skills from other business areas. All employees can proactively apply their talents where their skill sets can create the most value for patient outcomes and adopt new skills along the way. Our leadership team has actively supported 700 gigs in support of employee development and operational excellence.
What Got Us Here Won't Get Us There
At Sanofi, we recognize the significance of this moment. Each of us carries the power to reimagine what's possible in our R&D-driven, AI-powered, and patient-integrated world. When we embrace our collective purpose, we create a high-performance culture focused on improving people's lives. By boldly questioning our past, honestly assessing our present, and fearlessly reaching toward tomorrow, we aren't just preparing for the future—we're also shaping it.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 minutes ago
- Yahoo
Morgan Stanley Maintains a Sell Rating on Bristol-Myers Squibb (BMY), Sets a $34 PT
Bristol-Myers Squibb Company (NYSE:BMY) is one of the best . In a report released on July 13, Terence Flynn from Morgan Stanley maintained a Sell rating on Bristol-Myers Squibb Company (NYSE:BMY), setting a price target of $34.00. A pharmacy shelves stocked with pharmaceutical drugs awaiting distribution. The analyst based the rating on the company's current market standing and future prospects, reasoning that a key point of concern is Bristol-Myers Squibb Company's (NYSE:BMY) reliance on Cobenfy. Cobenfy is an approved drug for schizophrenia and is now being tested for Alzheimer's Disease Psychosis (ADP). However, the analyst stated that while ADP has considerable potential market with no approved therapies available, it is uncertain whether Cobenfy will succeed in the domain, as it depends on the results of the ongoing Phase 3 trials. Flynn also reasoned that the initial uptake for the drug has been slower than expected for the treatment of schizophrenia, which may falter investor confidence in Cobenfy's potential to drive positive future revenue growth. Bristol-Myers Squibb Company (NYSE:BMY) is a biopharmaceutical company that discovers, develops, and delivers advanced medicines for serious diseases. Its medicines fall into various therapeutic classes, including hematology, oncology, cardiovascular, immunology, and neuroscience. While we acknowledge the potential of BMY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
34 minutes ago
- Yahoo
Manchester United and Newcastle United join the race for Randal Kolo Muani
Manchester United and Newcastle United are keen to sign Randal Kolo Muani and have made contact regarding a potential move, according to Foot Mercato. Kolo Muani spent the latter half of last season on loan at Juventus, where he bagged 10 goals and three assists in 22 appearances across all competitions. Juve would like to prolong the Frenchman's stay in Turin to partner him with new signing Jonathan David. However, they will now have to fend off some competition. Despite having signed Matheus Cunha and recently agreeing a deal for Bryan Mbeumo, Man United are still working on more attacking acquisitions. They were one of the suitors for Eintracht Frankfurt star Hugo Ekitike, but he is set to join Liverpool. United are pivoting to other targets, one of whom is Kolo Muani. Newcastle were also keen on Ekitike and have wasted no time shifting their attention elsewhere. Alexander Isak's future is uncertain amid interest from Saudi Pro League club Al-Hilal, and the Magpies may need a replacement. Alongside Yoane Wissa, Kola Muani is now a transfer candidate as Newcastle aim to bolster their ranks ahead of a return to Champions League football. Paris Saint-Germain would ideally like to sanction a permanent sale or a loan with an obligation to buy for Kolo Muani.
Yahoo
34 minutes ago
- Yahoo
Jim Cramer on NVIDIA: 'Betting Against Jensen Has Been a Surefire Way to Lose Money'
NVIDIA Corporation (NASDAQ:NVDA) is one of the stocks Jim Cramer weighed in on. During the episode, Cramer noted that betting against the company's CEO has not been a good idea for a long time. He commented: 'When the company reported late May, with the ban on H20 sales still in place, Jensen came on Mad Money and he had this to say, keep the faith. 'Our president wants America to win, and he also recognizes that this is an important market, it's a very large market, and the revenues that it could generate for the United States is significant. It's just incredible. $50 billion this year. Look, we're talking about the size of a Boeing, not a Boeing plane, Boeing the company. This is an enormous market.' A close-up of a colorful high-end graphics card being plugged in to a gaming computer. NVIDIA (NASDAQ:NVDA) delivers advanced computing, graphics, and networking solutions across AI, gaming, robotics, and automotive sectors. The company's portfolio includes GPUs, cloud platforms, and enterprise software. While we acknowledge the potential of NVDA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio